Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.

INTRODUCTION: We characterized the safety and tolerability of empagliflozin in patients with type 2 diabetes (T2DM) randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in clinical trials.
METHODS: Pooled data were analyzed from patients with T2DM treated with placebo (N = 4203), empagliflozin 10 mg (N = 4221), or empagliflozin 25 mg (N = 4196) in 15 randomized phase I-III trials plus four extension studies. Adverse events (AEs) were assessed descriptively in participants who took at least one dose of study drug. AE incidence rates per 100 patient-years were calculated to adjust for differences in drug exposure between trials.
RESULTS: Total exposure was 7369, 7782, and 7754 patient-years in the placebo, empagliflozin 10 mg, and 25 mg groups, respectively. The incidence of any AEs, severe AEs, serious AEs, and AEs leading to discontinuation was no higher in participants treated with empagliflozin vs. placebo. Empagliflozin was not associated with an increased risk of hypoglycemia vs. placebo, except in participants on background sulfonylurea. The incidence of events consistent with urinary tract infection was similar across treatment groups (8.7-9.5/100 patient-years). Events consistent with genital infection occurred more frequently in participants treated with empagliflozin 10 and 25 mg (3.5 and 3.4/100 patient-years, respectively) than placebo (0.9/100 patient-years). The incidence of AEs consistent with volume depletion was similar across treatment groups (1.7-1.9/100 patient-years) but was higher with empagliflozin 10 mg and 25 mg vs. placebo in participants aged 75 years or older (3.2 and 3.0 vs. 2.3/100 patient-years, respectively). The rates of bone fractures, cancer events, renal AEs, venous thromboembolic events, hepatic injury, acute pancreatitis, lower limb amputations, and diabetic ketoacidosis were similar across treatment groups.
CONCLUSION: This analysis of pooled safety data based on more than 15,000 patient-years' exposure supports a favorable benefit-risk profile of empagliflozin in patients with T2DM. FUNDING: Boehringer Ingelheim Pharma GmbH.

RCT Entities:   Population Interventions Outcomes

Introduction

Empagliflozin is a potent and selective sodium glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus (T2DM). Inhibition of SGLT2 in patients with T2DM leads to increased urinary glucose excretion [1]. In addition, initiation of empagliflozin increases excretion of sodium, resulting in osmotic diuresis and reduced volume load [2, 3]. In placebo-controlled phase III trials, treatment with empagliflozin (10 or 25 mg) as monotherapy or add-on therapy improved glycemic control and led to reductions in weight and blood pressure in patients with T2DM [4-11]. Furthermore, in the EMPA-REG OUTCOME® trial, empagliflozin given in addition to standard of care reduced cardiovascular events, cardiovascular mortality, and incident or worsening nephropathy in patients with T2DM and established cardiovascular disease [12, 13].

An analysis of pooled safety data from clinical trials based on more than 9000 patient-years’ exposure showed that empagliflozin 10 and 25 mg were well tolerated in patients with T2DM [14]. Events consistent with genital infection were reported in a greater proportion of patients treated with empagliflozin than placebo. Empagliflozin was not associated with an increased risk of hypoglycemia vs. placebo, except in patients on background sulfonylurea and/or insulin. In this clinical trial setting, the incidences of events consistent with urinary tract infection (UTI), volume depletion, bone fractures, cancer, and decreased renal function were not increased with empagliflozin [14]. However, side effects in the empagliflozin product label include UTIs and volume depletion, especially in elderly patients [15].

An increased risk of diabetic ketoacidosis was not observed in clinical trials of empagliflozin. However, as loss of glucose in the urine leads to a negative energy balance and so to a decreased insulin-to-glucagon ratio, SGLT2 inhibition may lead to an increase in circulating ketone bodies, particularly in the fasting state [16], and there have been reports of diabetic ketoacidosis in post-marketing safety studies. Thus, the product label for empagliflozin includes a recommendation for healthcare professionals to assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis regardless of blood glucose level [15].

This paper describes the safety and tolerability of empagliflozin based on a large pool of patients with T2DM who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in 15 phase I–III clinical trials, including the EMPA-REG OUTCOME® trial.

Methods

Participants

Data were pooled from 14 trials of 8 days to 78 weeks’ duration [4–11, 17–22]; the 52-week extensions to the phase III trials of empagliflozin given as monotherapy, or as add on to metformin, metformin plus SU, and pioglitazone with or without metformin [23-26]; and the cardiovascular outcomes trial EMPA-REG OUTCOME® (median duration of treatment 2.6 years) [13].

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All participants gave signed and dated informed consent prior to inclusion.

Assessments and Data Analyses

Safety and tolerability were assessed on the basis of adverse events (AEs) reported by investigators, which were coded according to preferred terms in the Medical Dictionary for Regulatory Activities [MedDRA] version 18.0. A severe AE was defined as an AE judged by the investigator to be incapacitating or causing inability to work or to perform usual activities. A serious AE was defined as an AE that resulted in death, was immediately life-threatening, resulted in persistent or marked disability/incapacity, required or prolonged patient hospitalization, was a congenital anomaly/birth defect, or was deemed serious for any other reason. Safety topics of interest included confirmed hypoglycemic AEs (plasma glucose ≤3.9 mmol/L and/or requiring assistance); events consistent with UTI, genital infection, and volume depletion; bone fractures; cancer; decreased renal function; diabetic ketoacidosis; hepatic injury; acute pancreatitis; and amputations. As lower limb amputations were not usually captured in AE reports, the frequency of lower limb amputations was assessed on the basis of a manual review of the pooled safety data and AE narratives. Assessment of laboratory parameters included changes from baseline in hematocrit, parathyroid hormone, liver enzymes, bilirubin, electrolytes, and lipids, and estimated glomerular filtration rate (eGFR; according to the Modification of Diet in Renal Disease equation). Urine ketone levels (negative [normal], trace, 1+, ≥2+, ≥3+) were assessed on the basis of the worst recorded value on treatment.

Analyses of AEs were descriptive and based on participants who received at least one dose of study drug. Exposure-adjusted incidence rates were calculated per 100 patient-years as 100 × n/T, where n was the number of subjects with the event and T was the total patient-years at risk of the event. Patient-years at risk was defined as the time from the first dose to the onset of the first event (for participants with an event) or to the last dose plus 7 days (for participants without an event).

Results

Participant Disposition, Exposure and Baseline Characteristics

In total, 4203, 4221, and 4196 participants were treated with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively. Total exposure was 7369, 7782, and 7754 patient-years in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively. The participants came from Europe (39%), Asia (27%), North America (21%), and Latin America (11%) (Table 1). Baseline demographics and clinical characteristics were balanced among the treatment groups (Table 1).

Table 1

Demographics and baseline characteristics

	Placebo (N = 4203)	Empagliflozin 10 mg (N = 4221)	Empagliflozin 25 mg (N = 4196)
Male, n (%)	2700 (64.2)	2731 (64.7)	2745 (65.4)
Age, years	60.6 (9.7)	60.7 (9.5)	60.6 (9.7)
Race, n (%)
White	2765 (65.8)	2811 (66.6)	2787 (66.4)
Asian	1219 (29.0)	1209 (28.6)	1198 (28.6)
Black/African-American	183 (4.4)	171 (4.1)	174 (4.1)
Othera	36 (0.9)	29 (0.7)	35 (0.8)
Missing	0	1 (<0.1)	2 (<0.1)
Region, n (%)
Europe	1656 (39.4)	1662 (39.4)	1652 (39.4)
Asia	1124 (26.7)	1122 (26.6)	1111 (26.5)
North America (plus Australia and New Zealand)	857 (20.4)	868 (20.6)	859 (20.5)
Latin America	450 (10.7)	452 (10.7)	456 (10.9)
Africa/Middle East	116 (2.8)	117 (2.8)	118 (2.8)
Time since diagnosis, years, n (%)
≤1	227 (5.4)	252 (6.0)	256 (6.1)
>1–5	922 (21.9)	858 (20.3)	860 (20.5)
>5	3039 (72.3)	3096 (73.3)	3064 (73.0)
Missing	15 (0.4)	15 (0.4)	16 (0.4)
Number of background glucose-lowering medications, n (%)
0	525 (12.5)	523 (12.4)	524 (12.5)
1	1212 (28.8)	1221 (28.9)	1175 (28.0)
2	1880 (44.7)	1862 (44.1)	1900 (45.3)
Other	586 (13.9)	615 (14.6)	597 (14.2)
Weight, kgb	85.5 (19.6)	85.3 (19.5)	85.8 (19.6)
BMI, kg/m2 c	30.4 (5.4)	30.4 (5.5)	30.5 (5.5)
HbA1c, %d	8.06 (0.83)	8.05 (0.84)	8.04 (0.83)
FPG, mmol/Le	8.55 (2.31)	8.54 (2.33)	8.52 (2.30)
SBP, mmHgf	134.3 (16.6)	133.9 (16.2)	134.1 (16.5)
DBP, mmHgf	77.9 (9.7)	77.8 (9.6)	77.8 (9.4)
eGFR, mL/min/1.73 m2 g	79.1 (21.0)	79.3 (21.5)	79.2 (21.6)
eGFR, mL/min/1.73 m2, n (%)
≥90	1172 (27.9)	1204 (28.5)	1233 (29.4)
60 to <90	2298 (54.7)	2285 (54.1)	2216 (52.8)
30 to <60	726 (17.3)	722 (17.1)	728 (17.3)
<30	7 (0.2)	9 (0.2)	16 (0.4)
Missing	0	1 (<0.1)	3 (0.1)

Data are mean (SD), unless otherwise indicated, in participants who received at least one dose of study drug

BMI body mass index, eGFR estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD) equation, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, SBP systolic blood pressure, T2DM type 2 diabetes

aAmerican Indian/Alaska Native/Hawaiian/Pacific Islander

bPlacebo, n = 4182; empagliflozin 10 mg, n = 4201; empagliflozin 25 mg, n = 4177

cPlacebo, n = 4182; empagliflozin 10 mg, n = 4201; empagliflozin 25 mg, n = 4177

dPlacebo, n = 4203; empagliflozin 10 mg, n = 4219; empagliflozin 25 mg, n = 4195

ePlacebo, n = 4176; empagliflozin 10 mg, n = 4194; empagliflozin 25 mg, n = 4180

fPlacebo, n = 4145; empagliflozin 10 mg, n = 4165; empagliflozin 25 mg, n = 4142

gPlacebo, n = 4203; empagliflozin 10 mg, n = 4220; empagliflozin 25 mg, n = 4193

Summary of Adverse Events

The incidences of severe AEs, serious AEs, fatal AEs, and AEs leading to discontinuation were higher in the placebo group than in the empagliflozin groups (Table 2). The most common AEs occurred at similar or higher incidence rates in participants treated with placebo than empagliflozin (Table 2).

Table 2

Summary of adverse events

	Placebo (N = 4203)		Empagliflozin 10 mg (N = 4221)		Empagliflozin 25 mg (N = 4196)
	n (%)	Rate/100 patient-years	n (%)	Rate/100 patient-years	n (%)	Rate/100 patient-years
≥1 AE	3449 (82.1)	195.4	3401 (80.6)	167.2	3383 (80.6)	163.6
≥1 drug-related AEa	921 (21.9)	14.9	1144 (27.1)	18.6	1117 (26.6)	18.1
≥1 AE leading to discontinuation	540 (12.8)	7.6	490 (11.6)	6.5	484 (11.5)	6.4
≥1 severe AEb	718 (17.1)	10.8	634 (15.0)	8.9	682 (16.3)	9.6
≥1 serious AEc	1150 (27.4)	19.2	1020 (24.2)	15.5	1052 (25.1)	16.5
Fatal AE	122 (2.9)	1.6	100 (2.4)	1.3	83 (2.0)	1.1
AEs with frequency of ≥5% in any group (by MedDRA preferred term)
Hypoglycemia	956 (22.7)	16.1	977 (23.1)	15.9	952 (22.7)	15.5
Hyperglycemia	709 (16.9)	11.0	346 (8.2)	4.7	306 (7.3)	4.1
Urinary tract infection	523 (12.4)	7.7	528 (12.5)	7.4	510 (12.2)	7.2
Nasopharyngitis	424 (10.1)	6.1	417 (9.9)	5.7	408 (9.7)	5.6
Upper respiratory tract infection	292 (6.9)	4.2	285 (6.8)	3.8	288 (6.9)	3.9
Hypertension	291 (6.9)	4.1	205 (4.9)	2.7	218 (5.2)	2.9
Back pain	238 (5.7)	3.3	232 (5.5)	3.1	253 (6.0)	3.4
Dizziness	208 (4.9)	2.9	246 (5.8)	3.3	250 (6.0)	3.4
Diarrhea	247 (5.9)	3.5	219 (5.2)	2.9	212 (5.1)	2.8
Bronchitis	221 (5.3)	3.1	185 (4.4)	2.4	163 (3.9)	2.1
Influenza	219 (5.2)	3.1	173 (4.1)	2.3	199 (4.7)	2.6
Arthralgia	196 (4.7)	2.7	180 (4.3)	2.4	213 (5.1)	2.8

Data from participants treated with at least one dose of study drug

AE adverse event, MedDRA Medical Dictionary for Regulatory Activities

aIn opinion of investigator

bAE that is incapacitating or causing inability to work or to perform usual activities

cAE that results in death, is immediately life-threatening, results in persistent or significant disability/incapacity, requires or prolongs patient hospitalization, is a congenital anomaly/birth defect, or is deemed serious for any other reason

Hypoglycemia

The incidence of confirmed hypoglycemic AEs differed according to glucose-lowering medication used at baseline. The incidence of confirmed hypoglycemic adverse events was higher with empagliflozin than placebo in participants taking a sulfonylurea at baseline, but was similar between empagliflozin and placebo in other subgroups by background glucose-lowering medication (Table 3).

Table 3

Confirmed hypoglycemic adverse events by glucose-lowering medication used at baseline

	Placebo			Empagliflozin 10 mg			Empagliflozin 25 mg
	n/N	%	Rate/100 patient-years	n/N	%	Rate/100 patient-years	n/N	%	Rate/100 patient-years
Insulin usea
No	230/2595	8.9	5.9	240/2612	9.2	5.9	251/2607	9.6	6.1
Yes	676/1608	42.0	31.7	683/1609	42.4	32.1	659/1589	41.5	31.4
Sulfonylurea usea
No	595/2781	21.4	16.9	575/2801	20.5	15.4	571/2748	20.8	15.7
Yes	311/1422	21.9	12.3	348/1420	24.5	14.0	339/1448	23.4	13.0
Metformin usea
No	257/1275	20.2	17.3	251/1259	19.9	15.5	220/1255	17.5	13.5
Yes	649/2928	22.2	14.2	672/2962	22.7	14.6	690/2941	23.5	14.9
Metformin alone use
No	885/3607	24.5	17.1	903/3583	25.2	17.4	889/3594	24.7	16.8
Yes	21/596	3.5	2.4	20/638	3.1	1.9	21/602	3.5	2.2

Data from participants who received at least dose of study drug. Hypoglycemic adverse events are defined as those resulting in plasma glucose of at most 3.9 mmol/L and/or requiring assistance

aWith or without other glucose-lowering medication

Urinary Tract Infections

The incidence of events consistent with UTI was higher in female than male participants in all treatment groups, and was similar between empagliflozin and placebo in both male and female participants (Table 4). The incidence of such events was higher in participants aged 65 years or more in all treatment groups. Events consistent with UTI were mild or moderate in 96.7% of participants who experienced them and led to treatment discontinuation in a very small proportion of participants (0.3%, 0.6%, and 0.6% in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively). The proportions of participants with UTIs that required or prolonged hospitalization were similar in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups (0.9%, 0.6%, and 0.9%, respectively). In total, 700 participants had a history of chronic or recurrent UTI, whereas 10,861 participants had no such history. Events consistent with UTI were reported by a higher proportion of participants with a history of chronic or recurrent UTI (38.9%, 37.4%, and 36.5% in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively) than in participants without such a history (14.4%, 14.4%, and 13.7% in these groups, respectively). Complicated UTIs (pyelonephritis, urosepsis, or serious AEs consistent with UTI) were reported in 0.9%, 0.6%, and 0.9% of participants in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively. The mean change in HbA1c in patients with events consistent with UTI was not analyzed.

Table 4

Adverse events of special interest

	Placebo (N = 4203)			Empagliflozin 10 mg (N = 4221)			Empagliflozin 25 mg (N = 4196)
	n or n/N	%	Rate/100 patient-years	n or n/N	%	Rate/100 patient-years	n or n/N	%	Rate/100 patient-years
Events consistent with urinary tract infectiona	629	15.0	9.5	639	15.1	9.2	607	14.5	8.7
Sex
Male	193/2700	7.1	4.0	217/2731	7.9	4.3	206/2745	7.5	4.0
Female	436/1503	29.0	23.9	422/1490	28.3	21.7	401/1451	27.6	21.8
Age (years)
<50	75/531	14.1	12.4	59/533	11.1	7.9	64/544	11.8	8.8
50 to <65	281/2206	12.7	7.9	299/2176	13.7	8.3	257/2154	11.9	7.1
65 to <75	208/1184	17.6	10.5	204/1235	16.5	9.4	222/1213	18.3	10.2
≥75	65/282	23.0	13.0	77/277	27.8	16.8	64/285	22.5	13.6
Events consistent with genital infectionb	67	1.6	0.9	259	6.1	3.5	251	6.0	3.4
Sex
Male	33/2700	1.2	0.7	135/2731	4.9	2.6	107/2745	3.9	2.0
Female	34/1503	2.3	1.5	124/1490	8.3	5.2	144/1451	9.9	6.6
Age (years)
<50	14/531	2.6	2.1	44/533	8.3	5.8	37/544	6.8	4.8
50 to <65	29/2206	1.3	0.8	135/2176	6.2	3.5	129/2154	6.0	3.4
65 to <75	20/1184	1.7	0.9	63/1235	5.1	2.6	70/1213	5.8	2.9
≥75	4/282	1.4	0.7	17/277	6.1	3.2	15/285	5.3	2.8
Events consistent with volume depletionc	126	3.0	1.7	138	3.3	1.8	142	3.4	1.9
Age (years)
<50	5/531	0.9	0.7	5/533	0.9	0.6	10/544	1.8	1.3
50 to <65	48/2206	2.2	1.2	48/2176	2.2	1.2	53/2154	2.5	1.4
65 to <75	60/1184	5.1	2.8	68/1235	5.5	2.9	63/1213	5.2	2.6
≥75	13/282	4.6	2.3	17/277	6.1	3.2	16/285	5.6	3.0
Diuretic use at baseline
Yes	74/1419	5.2	2.7	76/1451	5.2	2.6	80/1429	5.6	2.8
No	52/2784	1.9	1.1	62/2770	2.2	1.3	62/2767	2.2	1.3
Loop diuretic use at baseline
Yes	31/424	7.3	3.5	41/400	10.3	5.0	40/433	9.2	4.4
No	95/3779	2.5	1.5	97/3821	2.5	1.4	102/3763	2.7	1.5
Bone fracturesd	123	2.9	1.7	119	2.8	1.6	105	2.5	1.4
eGFR at baseline (mL/min/1.73 m2)
≥90	15/1172	1.3	0.8	27/1204	2.2	1.4	23/1233	1.9	1.1
60 to <90	70/2298	3.0	1.8	57/2285	2.5	1.4	53/2216	2.4	1.3
45 to <60	30/529	5.7	2.8	23/530	4.3	2.0	21/531	4.0	1.8
30 to <45	7/197	3.6	1.6	12/192	6.3	3.0	8/197	4.1	1.9
<30	1/7	14.3	7.9	0/9	0	0	0/16	0	0
Cancer eventse	95	2.3	1.3	121	2.9	1.6	119	2.8	1.5
With onset ≥6 months from start of treatment/participants with exposure ≥6 months	76/3159	2.4	1.4	103/3270	3.1	1.8	86/3203	2.7	1.5
Bladder cancerf	2	0.1	0.0	4	0.1	0.1	7	0.2	0.1
Renal cancerg	5	0.2	0.1	4	0.1	0.1	3	0.1	0.1
Breast cancerh	4	0.1	0.1	3	0.1	0.1	3	0.1	0.1
Melanomai	2	<0.1	<0.1	4	0.1	0.1	3	0.1	0.1
Lung cancerj	7	0.2	0.1	11	0.3	0.2	9	0.3	0.2
Events consistent with decreased renal functionk	159	3.8	2.2	137	3.2	1.8	141	3.4	1.8
eGFR at baselinek (mL/min/1.73 m2)
≥90	13/1172	1.1	0.7	9/1204	0.7	0.5	10/1233	0.8	0.5
60 to <90	56/2298	2.4	1.4	56/2285	2.5	1.4	53/2216	2.4	1.3
45 to <60	55/529	10.4	5.2	45/530	8.5	4.0	42/531	7.9	3.7
30 to <45	32/197	16.2	7.9	24/192	12.5	6.2	34/197	17.3	8.9
<30	3/7	42.9	37.7	3/9	33.3	21.4	2/16	12.5	7.6
Acute kidney injuryl	38	0.9	0.5	28	0.7	0.4	24	0.6	0.3
Hepatic injurym	151	3.6	2.1	106	2.5	1.4	127	3.0	1.7
Acute pancreatitisl	4	0.1	0.1	1	<0.1	<0.1	4	0.1	0.1
Diabetic ketoacidosisn	5	0.1	0.1	5	0.1	0.1	1	<0.1	<0.1
Venous thromboembolic eventso	23	0.5	0.3	11	0.3	0.1	26	0.6	0.3
Lower limb amputations	46	1.1	–	46	1.1	–	48	1.1	–
Events potentially related to lower limb amputations
Peripheral artery obstructive disease events	96	2.3	–	98	2.3	–	112	2.7	–
Diabetic foot-related events	109	2.6	–	94	2.2	–	106	2.5	–
Relevant infection events	74	1.8	–	79	1.9	–	80	1.9	–
Wound events	57	1.4	–	64	1.5	–	63	1.5	–

Data from participants who received at least one dose of study drug

AE adverse event, eGFR estimated glomerular filtration rate by Modification of Diet in Renal Disease [MDRD] equation, SMQ standardized MedDRA query

aBased on 79 MedDRA preferred terms; 25 were reported, of which urinary tract infection, asymptomatic bacteriuria, and cystitis were the most frequent

bBased on 88 MedDRA preferred terms; 31 were reported, of which balanoposthitis, vulvovaginal mycotic infection, and vulvovaginal candidiasis were the most frequent

cBased on eight MedDRA preferred terms; six were reported, of which hypotension, syncope, and dehydration were the most frequent

dBased on 62 MedDRA preferred terms; 41 were reported, of which foot fracture, rib fracture, and ankle fracture were the most frequent

eBased on two sub-SMQs

fBased on reported preferred terms: bladder cancer/bladder transitional cell carcinoma/transitional cell carcinoma

gBased on MedDRA high level term, reported preferred terms: renal cancer metastatic/renal cell carcinoma/renal cell carcinoma stage I/renal cell carcinoma stage II/clear cell renal cell carcinoma

hBased on MedDRA high level term, reported preferred terms: breast cancer/invasive ductal breast carcinoma/intraductal proliferative breast carcinoma

iBased on MedDRA high level term, reported preferred terms: malignant melanoma/malignant melanoma in situ/metastatic malignant melanoma

jBased on MedDRA high level terms, reported preferred terms: lung neoplasm malignant//bronchial carcinoma/lung cancer metastatic/lung adenocarcinoma/squamous cell carcinoma of lung/large cell lung cancer/lung squamous cell carcinoma stage III/non-small cell lung cancer

kBased on narrow SMQ acute renal failure

lBased on MedDRA preferred term

mBased on four narrow sub-SMQs

nBased on three MedDRA preferred terms

oBased on one narrow SMQ

Genital Infections

The incidence of events consistent with genital infection was higher in female than male participants in all treatment groups, and was higher with empagliflozin than placebo in both male and female participants and in all age groups (Table 4). Events consistent with genital infection were mild or moderate in 99% of participants who experienced them and rarely led to treatment discontinuation (<0.1%, 0.6%, and 0.5% of participants in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively). The proportion of participants with genital infections reported as serious adverse events was low (0.1%, 0.2%, and 0.1% in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively). In total, 174 participants had a history of chronic or recurrent genital infection, whereas 11,387 participants had no history of chronic or recurrent genital infection. The proportion of participants with events consistent with genital infection was higher in participants with a history of chronic or recurrent genital infection (9.7%, 32.0%, and 27.4% in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively) than in participants without such a history (1.5%, 5.9%, and 5.9%, respectively). The mean change in HbA1c in patients with events consistent with genital infection was not analyzed.

Volume Depletion

The incidence of events consistent with volume depletion was similar between placebo and empagliflozin in all age subgroups, apart from a higher incidence with empagliflozin 10 mg and empagliflozin 25 mg vs. placebo in participants aged 75 years or older (3.2 and 3.0 vs. 2.3 per 100 patient-years, respectively). The incidence of events consistent with volume depletion was similar between placebo and empagliflozin irrespective of use of diuretics at baseline. In participants receiving loop diuretics at baseline, the incidence of events consistent with volume depletion was 3.5, 5.0 and 4.4 per 100 patient-years with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively.

Cancer

The incidence of cancer events, and of cancer events with an onset more than 6 months from the start of treatment, was similar between the placebo and empagliflozin groups. No imbalance was observed between empagliflozin and placebo in the incidence of any specific type of cancer (Table 4).

Renal AEs and Laboratory Parameters

Small decreases in eGFR were observed in all treatment groups, with larger decreases in participants treated with placebo than empagliflozin (Table 5). The incidence of events consistent with decreased renal function (narrow standardized MedDRA query “acute renal failure”) was similar in the placebo and empagliflozin groups; the incidence of these events was higher in participants with moderate renal impairment (eGFR >30 to <60 mL/min/1.73 m2) than in those with no/mild renal impairment (Table 4). The incidence of acute kidney injury (MedDRA preferred term) was similar in the placebo and empagliflozin groups (Table 4). Serum uric acid decreased more in participants treated with empagliflozin than placebo (Table 5). Empagliflozin was not associated with an increase in the incidence of nephrolithiasis (0.9, 0.6, and 0.5 per 100 patient-years in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively), renal colic (0.1, 0.2, and 0.1 per 100 patient-years in these groups, respectively), or gout (0.6, 0.6, and 0.5 per 100 patient-years in these groups, respectively).

Table 5

Laboratory results

	Placebo			Empagliflozin 10 mg			Empagliflozin 25 mg
	n	Baseline	Change from baselinea	n	Baseline	Change from baselinea	n	Baseline	Change from baselinea
Hematocrit, %	4043	41.7 (5.3)	0.5 (4.2)	4078	41.8 (5.3)	4.1 (4.9)	4030	41.9 (5.4)	4.3 (4.7)
Hemoglobin, g/L	4053	136 (14)	−1 (10)	4089	137 (14)	8 (12)	4041	137 (14)	8 (12)
Uric acid, µmol/L	4047	322 (134)	−1 (101)	4095	316 (131)	−31 (100)	4042	318 (131)	−34 (102)
Serum creatinine, µmol/L	4104	86 (19)	4 (18)	4136	86 (19)	3 (15)	4101	86 (19)	3 (14)
eGFR, mL/min/1.73 m2	4101	79.1 (21.0)	−2.7 (12.8)	4133	79.3 (21.5)	−1.7 (12.9)	4099	79.2 (21.6)	−1.9 (13.2)
Aspartate aminotransferase, U/L	4102	15 (13)	−0 (19)	4136	15 (11)	−1 (15)	4099	15 (11)	−1 (36)
Alanine aminotransferase, U/L	4104	20 (15)	−1 (25)	4136	20 (14)	−2 (16)	4099	20 (14)	−2 (33)
Alkaline phosphatase, U/L	4104	66 (31)	3 (27)	4136	67 (32)	1 (27)	4099	67 (33)	1 (23)
Total bilirubin, µmol/L	4052	8.9 (3.3)	−0.0 (2.5)	4096	8.8 (3.0)	0.2 (3.2)	4044	9.0 (3.1)	0.1 (4.9)
25-Hydroxyvitamin D, nmol/Lb	291	75.4 (35.7)	2.6 (40.0)	307	77.9 (33.7)	5.7 (35.2)	307	77.0 (34.6)	9.1 (43.1)
Urinary N-telopeptide (NTx)/creatinine ratio (nM/mM Cre)b	280	41 (24)	−2 (17)	295	40 (20)	3 (19)	290	40 (21)	6 (27)
Parathyroid hormone, pmol/Lb	285	4.2 (1.8)	−0.3 (1.4)	308	4.2 (1.7)	−0.0 (1.3)	307	4.4 (5.2)	−0.3 (4.6)
Electrolytes
Sodium, mmol/L	4047	141 (2)	−0 (2)	4095	141 (2)	0 (2)	4041	141 (2)	0 (2)
Potassium, mmol/L	4045	4.2 (0.3)	0.0 (0.3)	4094	4.2 (0.3)	−0.0 (0.3)	4041	4.2 (0.3)	−0.0 (0.3)
Calcium, mmol/L	4047	2.4 (0.1)	−0.0 (0.1)	4095	2.4 (0.1)	−0.0 (0.1)	4042	2.4 (0.1)	−0.0 (0.1)
Magnesium, mmol/L	4031	0.9 (0.1)	−0.0 (0.1)	4079	0.9 (0.1)	0.0 (0.1)	4026	0.9 (0.1)	0.1 (0.1)
Phosphate, mmol/L	4030	1.2 (0.1)	0.0 (0.1)	4079	1.2 (0.1)	0.0 (0.1)	4026	1.2 (0.1)	0.0 (0.1)
Bicarbonate, mmol/L	4023	24.8 (2.8)	−0.5 (3.0)	4066	24.8 (2.8)	−0.9 (3.0)	4021	24.8 (2.8)	−0.9 (3.0)
Total cholesterol, mmol/L	4014	4.4 (1.1)	0.1 (1.0)	4035	4.4 (1.2)	0.2 (1.0)	3997	4.5 (1.1)	0.2 (1.0)
HDL-cholesterol, mmol/L	4015	1.2 (0.3)	0.0 (0.2)	4034	1.2 (0.3)	0.0 (0.2)	3997	1.2 (0.3)	0.1 (0.2)
LDL-cholesterol, mmol/L	3986	2.4 (1.0)	0.1 (0.8)	3993	2.4 (1.0)	0.1 (0.8)	3967	2.4 (0.9)	0.1 (0.8)
LDL/HDL cholesterol ratio	3986	2.1 (1.0)	0.1 (1.0)	3993	2.1 (0.9)	0.0 (0.8)	3967	2.1 (1.0)	0.0 (0.8)
Triglycerides, mmol/L	4014	1.9 (1.3)	0.1 (1.5)	4035	1.9 (1.6)	0.0 (1.4)	3997	1.9 (1.5)	0.1 (1.5)
Apolipoprotein A-I, g/L	3609	1.26 (0.06)	0.00 (0.04)	3627	1.26 (0.06)	0.01 (0.04)	3616	1.26 (0.06)	0.01 (0.05)
Apolipoprotein B, g/L	3609	0.95 (0.52)	0.08 (0.43)	3627	0.95 (0.53)	0.10 (0.44)	3617	0.96 (0.52)	0.11 (0.42)

Data are mean (SD) in participants who received at least one dose of study drug and had laboratory values available at baseline and on treatment. Data are normalized to a standard reference range, except for eGFR and lipids

eGFR estimated glomerular filtration rate by Modification of Diet in Renal Disease [MDRD] equation, HDL high-density lipoprotein, LDL low-density lipoprotein

aChange from baseline at last value on treatment

bUrinary N-telopeptide/creatinine ratio, 25-hydroxyvitamin D, and parathyroid hormone levels were only recorded in two monotherapy trials [8, 19]

Hepatic AEs and Laboratory Parameters

The incidence of events consistent with hepatic injury was similar in the placebo and empagliflozin groups (Table 4). There were no clinically relevant changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or bilirubin in any treatment group (Table 5). Elevations in liver enzymes to at least three times the upper limit of normal (ULN) were rare in all treatment groups and no more common with empagliflozin than with placebo, but elevations in ALT and/or AST at least five times ULN were more frequently observed with empagliflozin vs. placebo. The proportion of participants who had ALT and/or AST at least three times ULN with bilirubin at least two times ULN was similar in the placebo and empagliflozin groups (Table 6). Elevations in liver enzymes were mainly explained by viral infections or the effects of concomitant medication. No cases met Hy’s law criteria.

Table 6

Elevations in liver enzymes and bilirubin

	Placebo (N = 4203)	Empagliflozin 10 mg (N = 4221)	Empagliflozin 25 mg (N = 4196)
ALT and/or AST ≥3 × ULN	59 (1.4)	41 (1.0)	38 (0.9)
ALT and/or AST ≥5 × ULN	9 (0.2)	17 (0.4)	21 (0.5)
ALT and/or AST ≥3 × ULN with bilirubin ≥2 × ULN	2 (<0.1)	5 (0.1)	5 (0.1)

Data are n (%) in participants who received at least one dose of study drug

ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal

Hematocrit and Venous Thromboembolic Events

Hemoglobin and hematocrit increased in participants treated with empagliflozin, with no increases in the placebo group (Table 5). The incidence of venous thromboembolic events was low in all treatment groups (0.3, 0.1, and 0.3 per 100 patient-years in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively) (Table 4).

Electrolytes, Parathyroid Hormone, and Bone Fractures

No clinically meaningful changes in serum electrolytes, alkaline phosphatase, 25-hydroxyvitamin D, urinary N-telopeptide (NTx)/creatinine ratio, or parathyroid hormone were observed in any treatment group (Table 5). The incidence of bone fractures was similar across treatment groups (1.7, 1.6, and 1.4 per 100 patient-years in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively). The proportion of participants with bone fractures was greater in participants with moderate renal impairment (eGFR >30 to <60 mL/min/1.73 m2) than in those with no/mild renal impairment (Table 4).

Lipid Parameters

There was a small increase from baseline in LDL-cholesterol and total cholesterol in all treatment groups, including the placebo group. There was a small increase from baseline in HDL-cholesterol with empagliflozin 25 mg. No change in the LDL-cholesterol/HDL-cholesterol ratio was observed with empagliflozin 10 or 25 mg. There was a small increase in triglycerides in the placebo and empagliflozin 25 mg groups, with no change in the empagliflozin 10 mg group (Table 5). There were no relevant changes in apolipoprotein A-I in any treatment group. Increases in apolipoprotein B were similar in the placebo and empagliflozin groups (Table 5).

Diabetic Ketoacidosis

The proportion of participants who had urine ketone levels at least 1+ was greater in the empagliflozin groups than in the placebo group (Table 7), but the proportion of participants with diabetic ketoacidosis AEs was similar between groups. Diabetic ketoacidosis was reported in 5 (0.1%), 5 (0.1%), and 1 (<0.1%) participants in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively. The incidence of diabetic ketoacidosis was 0.1, 0.1, and less than 0.1/100 patient-years in these groups, respectively. Two participants discontinued treatment with empagliflozin (10 mg) because of diabetic ketoacidosis AEs. No diabetic ketoacidosis AEs were considered to be related to study drug by the investigator. All participants recovered, except for one participant in the empagliflozin 10 mg group for whom the outcome was unknown (at the last follow-up, this participant was scheduled for hospital discharge 5 days after admission for the event). There were no clinically meaningful changes in bicarbonate levels in any treatment group (Table 5).

Table 7

Urine ketone levels: worst recorded measurement on treatment

	Placebo (N = 3645)	Empagliflozin 10 mg (N = 3682)	Empagliflozin 25 mg (N = 3636)
Negative	2973 (81.6)	2822 (76.6)	2757 (75.8)
Trace	511 (14.0)	535 (14.5)	508 (14.0)
1+	144 (4.0)	256 (7.0)	291 (8.0)
2+	15 (0.4)	58 (1.6)	73 (2.0)
3+	2 (0.1)	11 (0.3)	7 (0.2)

Data are n (%) in participants who received at least one dose of study drug and had ketone values available at baseline and on treatment

Acute Pancreatitis

Acute pancreatitis was reported in 4 (0.1%), 1 (<0.1%), and 4 (0.1%) participants in the placebo, empagliflozin 10 mg, and empagliflozin 25 mg groups, respectively. The incidence of acute pancreatitis was 0.1, less than 0.1, and 0.1/100 patient-years in these groups, respectively (Table 4).

Lower Limb Amputations

The frequency of lower limb amputations, based on a manual review of the pooled safety data and AE narratives, was 1.1% in all treatment groups (Table 4). Most (131 of 140) cases of lower limb amputation occurred in the EMPA-REG OUTCOME® trial (see Table S1 in the supplementary material). In the EMPA-REG OUTCOME® trial, the proportion of participants with lower limb amputations was similar in participants treated with placebo (1.8%) and empagliflozin (1.9%). Toe amputations occurred in 0.9% of participants in the placebo group and 1.3% of participants in the pooled empagliflozin group. In both the empagliflozin and placebo groups, the frequency of lower limb amputations was higher in participants with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m2) than in those with no/mild renal impairment, and in those using insulin at baseline (see Table S1 in the supplementary material). The frequency of lower limb amputations was higher in participants with a history of peripheral artery disease, microvascular disease, or diabetic foot in all treatment groups. There was no clinically significant difference in the frequency of lower limb amputations between the placebo and empagliflozin groups in subgroups by gender, age, use of diuretics or loop diuretics at baseline, use of concomitant glucose-lowering medications at baseline, or cardiovascular comorbidities (other than peripheral artery disease) (see Table S1 in the supplementary material). The incidences of events potentially related to amputations (peripheral artery obstructive disease events, diabetic foot-related events, relevant infection events, and wound events) were similar in the placebo and empagliflozin groups (Table 4).

Discussion

This comprehensive analysis of pooled safety data based on more than 15,000 patient-years’ exposure to empagliflozin was undertaken to characterize the safety and tolerability of empagliflozin in patients with T2DM. The results confirmed that empagliflozin is well tolerated in this patient population.

Hypoglycemia is a major concern in patients with T2DM [27]. In this large data set, empagliflozin was not associated with an increased risk of hypoglycemia compared with placebo, except for in participants on background sulfonylurea. Empagliflozin would not be expected to be associated with an increased risk of hypoglycemia given its insulin-independent mechanism of action [1]. However, sulfonylureas, which stimulate insulin secretion, are associated with an increased risk of hypoglycemia [27], and an increase in hypoglycemia has also been reported when other SGLT2 inhibitors are used in combination with a sulfonylurea [28, 29]. When empagliflozin is used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin should be considered to reduce the risk of hypoglycemia [15].

Treatment with empagliflozin leads to transient natriuresis and increases in urine volume [2, 3]. The potential for hypotension in patients treated with empagliflozin is acknowledged in the prescribing information [15], particularly in patients who are elderly. In this large data set, the incidence of events consistent with volume depletion was similar between empagliflozin and placebo, except for a greater incidence with empagliflozin in participants aged 75 years or older and in participants receiving loop diuretics at baseline.

In this analysis of pooled data, the incidence of events consistent with UTI was similar in participants treated with empagliflozin and placebo. The incidence of events consistent with genital infection was higher in participants treated with empagliflozin than with placebo, but such events were mild or moderate in most participants and rarely led to treatment discontinuation. An increased risk of genital infections has also been observed with other SGLT2 inhibitors [30, 31].

On the basis of a meta-analysis of phase IIb and phase III clinical trials, the US Food and Drug Administration warned that the SGLT2 inhibitor dapagliflozin may increase the risk of bladder cancer [32] and this is acknowledged in the dapagliflozin product label [33]. Several post-marketing studies are ongoing to ascertain the level of risk. The available safety data for empagliflozin do not suggest an association between empagliflozin and malignancies in patients with T2DM.

Small decreases in eGFR were observed in all treatment groups, with larger declines in the placebo group than in the empagliflozin groups. In the EMPA-REG OUTCOME® trial, an initial decrease in eGFR was observed with empagliflozin. Thereafter, during long-term administration, eGFR remained stable in patients treated with empagliflozin and declined steadily in the placebo group. After cessation of study drug, eGFR increased in the empagliflozin groups, such that eGFR was significantly higher with empagliflozin than placebo at the post-treatment follow-up visit [12]. These observations suggest that the initial decrease in eGFR in patients treated with empagliflozin is due to hemodynamic effects and that empagliflozin has the potential to slow decline in renal function in patients with T2DM [12]. Of note, in our analysis, there was no increase in the incidence of events consistent with decreased renal function, including acute kidney injury, with empagliflozin vs. placebo.

It has been hypothesized that SGLT2 inhibitors might increase the risk of bone fractures because of modulation of renal reabsorption of calcium and phosphate [34, 35]. In this large data set, the incidence of bone fractures was similar in participants treated with empagliflozin and placebo. There were no changes from baseline in calcium or phosphate levels with empagliflozin, and no notable changes from baseline in other bone markers with empagliflozin. Previous studies have found no notable changes in calcium or phosphate levels with empagliflozin in patients with T2DM and chronic kidney disease [4] or in patients with T2DM and established cardiovascular disease [13].

Increases in HDL-cholesterol and LDL-cholesterol have been observed in some trials of empagliflozin [5-8], which may be partly due to hemoconcentration [36]. In this pooled analysis, small increases in LDL-cholesterol were observed in the empagliflozin groups; small increases in HDL-cholesterol were observed in the empagliflozin 25 mg group. In this pooled analysis of data from the clinical trial setting, increased urine ketone levels were reported in a greater proportion of participants on empagliflozin than placebo, but the incidence of diabetic ketoacidosis was very low and no higher in participants treated with empagliflozin than placebo. The incidence of events consistent with hepatic injury was similar in participants treated with empagliflozin and placebo.

Regulators have recently completed a review of the available data for possible associations between the SGLT2 inhibitor class and lower limb amputations, concluding that canagliflozin may increase the risk of lower limb amputation [37, 38]. The US Food and Drug Administration has issued a boxed warning to the label for canagliflozin describing the increased risk of leg and foot amputations [38]. A review of the available data for possible associations between SGLT2 inhibitors and acute pancreatitis is ongoing. No evidence of an association between empagliflozin and lower limb amputations or acute pancreatitis was found in this large data set from the clinical trial setting.

Strengths of this analysis include the large sample size and exposure. Limitations include that the studies were of varying durations and that differences between groups were not compared using modelled analyses. The analysis of lower limb amputations should be interpreted with caution because of the manual retrieval and validation of such cases. Overall, the results of this analysis of pooled safety data support a favorable benefit–risk profile of empagliflozin in patients with T2DM.

Conclusion

In this pooled analysis based on more than 15,000 patient-years’ exposure to empagliflozin in placebo-controlled trials, empagliflozin 10 and 25 mg were well tolerated in patients with T2DM. Empagliflozin was not associated with a higher rate of hypoglycemic events compared with placebo, except in participants on background sulfonylurea. The incidence of AEs consistent with volume depletion was similar between empagliflozin and placebo, except for a higher incidence with empagliflozin in participants aged 75 years or older and in participants receiving loop diuretics at baseline. Genital infections, but not UTIs, were more frequent in participants treated with empagliflozin than placebo. The incidences of bone fractures, cancer events, renal adverse events, venous thromboembolic events, hepatic injury, acute pancreatitis, lower limb amputations, and diabetic ketoacidosis were not increased with empagliflozin compared with placebo. Further information on the safety and tolerability profile of empagliflozin will be provided by post-marketing surveillance.

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 21 kb)